News

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

Taipei, Taiwan. January 6, 2021 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development …

ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

1. Presentation number: 397P / Poster: ID 680 Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients Presenter: Ching-Liang Ho MD, et.al. Department of …

OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort TAIPEI, Taiwan, November 19, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: 4174), …

Company Announcement on Board Resolutions

Please refer to http://www.obipharma.com/2020/09/company-announcement-on-board-resolution/?lang=zh-hant for details.

OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

Presentation to highlight the scientific characteristics of the novel first-in-class anti Globo H antibody-drug conjugate (ADC), OBI-999. TAIPEI, Taiwan, Sept 14, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid …

Poster Presentations at AACR 2020 Virtual Annual Meeting II

Session PO ET04.02 Identification of molecular targets 2 Title: The role of Globo H in cancer cell survival Presenter: Tzer-Min Kuo, PhD, et. al., OBI Pharma, Inc., Taipei, Taiwan Virtual …

OBI Pharma Announces Poster Presentations at AACR 2020 Virtual Annual Meeting II

Poster Presentations to highlight the role of the Globo H antigen in cancer cell survival and its prevalence in different tumor types TAIPEI, Taiwan, June 16, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: …

OBI Pharma Posters at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk …

OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 antigens in different tumor types TAIPEI, Taiwan, May 20, 2020 — OBI Pharma, Inc. (TPEx: 4174), a …

OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic

TAIPEI, TAIWAN. APRIL 8, 2020– OBI Pharma has been closely monitoring the impact of the COVID-19 pandemic worldwide. We realize the intense challenges that patients and our clinical research investigators …